ABCL — AbCellera Biologics Inc. Stock Price, Chart & AI Report

Negative Oct 12, 2026 • 20:25 UTC Zacks Investment Research • Zacks.Com

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates

Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.

NRIX ABCL Q3 earnings earnings surprise revenue beat biomedical genetics Zacks Rank

Sentiment note

Expected to post a quarterly loss of $0.18 per share with revenues declining 39.3% year-over-year. Consensus EPS estimates have been revised 1.8% lower over the last 30 days, indicating deteriorating expectations.

Positive Oct 12, 2026 • 14:00 UTC GlobeNewswire Inc. • Researchandmarkets.Com

Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera

The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.

CRL TWST ABCL synthetic antibody library AI-driven drug discovery therapeutic antibodies phage display yeast display

Sentiment note

Featured as a prominent player in a market experiencing rapid expansion supported by rising demand for therapeutic antibodies and advanced discovery technologies.

Neutral Aug 14, 2025 • 11:23 UTC The Motley Fool • Jesterai

Prelude Cuts Q2 Losses and Costs 13%

Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.

PRLD ABCL oncology cancer therapy clinical-stage drug development protein degraders

Sentiment note

Mentioned as a continued collaboration partner with no significant new developments

Positive Jul 30, 2025 • 17:00 UTC GlobeNewswire Inc. • Delveinsight

Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight

The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.

ABCL ABSI TWST TMO antibody discovery biologics monoclonal antibodies therapeutic development

Sentiment note

Highlighted as a notable company in the antibody discovery market with innovative approaches

Unknown Jun 13, 2024 • 09:40 UTC The Motley Fool • newsfeedback@fool.com (Cory Renauer)

Down 57%, Is AbCellera Biologics a Buy on the Dip?

Wall Street analysts say this drug developer can more than double your money.

ABCL LLY investing

Unknown May 8, 2024 • 08:30 UTC The Motley Fool • newsfeedback@fool.com (Motley Fool Transcribing)

AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript

ABCL earnings call for the period ending March 31, 2024.

ABCL earningscall-transcripts

Unknown May 7, 2024 • 22:05 UTC Zacks Investment Research • Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates

AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ABCL RNA

Unknown May 1, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CYTK ABCL

Unknown Apr 30, 2024 • 14:01 UTC Zacks Investment Research • Zacks Equity Research

Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for

AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABCL ILMN

Unknown Feb 21, 2024 • 04:00 UTC The Motley Fool • newsfeedback@fool.com (Motley Fool Transcribing)

AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript

ABCL earnings call for the period ending December 31, 2023.

ABCL earningscall-transcripts

Unknown Feb 21, 2024 • 00:00 UTC Zacks Investment Research • Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for AbCellera Biologics Inc. (ABCL) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

ABCL

Unknown Feb 12, 2024 • 22:25 UTC Zacks Investment Research • Zacks Equity Research

Beyond Air, Inc. (XAIR) Reports Q3 Loss, Misses Revenue Estimates

Beyond Air, Inc. (XAIR) delivered earnings and revenue surprises of 18.03% and 20.20%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

XAIR ABCL